World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
64576
World Ranking
3434
National Ranking
342

Stan B. Kaye publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stan B. Kaye sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 765 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stan B. Kaye D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stan B. Kaye sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 122 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Stan B. Kaye is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research broadly spans the field of Medicine, with specific focus on subfields such as Pulmonary and Respiratory Medicine, Reproductive Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, and Epidemiology.

The main topics covered in their work include ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, radiomics and machine learning in medical imaging, lung cancer diagnosis and treatment, immune cell function and interaction, advanced X-ray and CT imaging, and lung cancer treatments and mutations.

Recent publications by Stan B. Kaye include the following:

  • Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer, 2021, EMBO Molecular Medicine
  • Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation, 2020, Lung Cancer
  • A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules, 2022, EBioMedicine
  • Faecal immunochemical testing in symptomatic patients to prioritize investigation: diagnostic accuracy from NICE FIT Study, 2021, British journal of surgery
  • Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial, 2021, ESMO Open

Stan B. Kaye has frequently published in a range of venues including EMBO Molecular Medicine, EBioMedicine, Lung Cancer, British journal of surgery, and ESMO Open.

Collaboration has been a notable aspect of their work, with frequent co-authors including Michał Marek Hoppe, Patrick Jaynes, Joanna D. Wardyn, Tuan Zea Tan, and Stefanus Lie.

Best Publications

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Carboplatin or cisplatin

    A.H. Calvert;A. Horwich;E.S. Newlands;R. Begent

  • International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

    GM Mead;SP Stenning;P Cook;SD Fossa

  • Rethinking ovarian cancer: recommendations for improving outcomes

    Sebastian Vaughan;Jermaine I. Coward;Robert C. Bast;Andy Berchuck

  • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau

  • Ovarian cancer: strategies for overcoming resistance to chemotherapy

    Roshan Agarwal;Stan B. Kaye

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

    Martine J. Piccart;Kamma Bertelsen;Keith James;Jim Cassidy

  • Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

    Paul A. Vasey;Stan B. Kaye;Rosemary Morrison;Chris Twelves

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud

  • Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

    J Baselga;D Rischin;M Ranson;H Calvert

  • Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    T Eisen;T Ahmad;K T Flaherty;M Gore

  • Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

    Paul Vasey;Gordon C Jayson;Alan Gordon;Hani Gabra

  • Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

    Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker

  • Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid

  • Beyond chemotherapy: targeted therapies in ovarian cancer

    Timothy A. Yap;Craig P. Carden;Craig P. Carden;Stan B. Kaye;Stan B. Kaye

  • Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

    J. Nemunaitis;F. Khuri;I. Ganly;J. Arseneau

  • "BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations

    David S.P. Tan;Christian Rothermundt;Karen Thomas;Elizabeth Bancroft

  • Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

    Stan B. Kaye;Jan Lubinski;Ursula Matulonis;Joo Ern Ang

Frequent Co-Authors

Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Martin Gore
Martin Gore Royal Marsden NHS Foundation Trust
Ian Judson
Ian Judson Institute of Cancer Research
David J. Kerr
David J. Kerr University of Oxford
Paul Workman
Paul Workman Institute of Cancer Research
Gerhardt Attard
Gerhardt Attard University College London
Jim Cassidy
Jim Cassidy University of Glasgow
Jan H.M. Schellens
Jan H.M. Schellens Utrecht University
Alan Ashworth
Alan Ashworth University of California, San Francisco
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexible or alternative ways to begin, several online degree options are available. For those already working as registered nurses, pursuing the cheapest rn to bsn online programs can be an affordable step toward career advancement, higher salaries, and broader clinical responsibilities.

Non-nurses or individuals with a bachelor’s degree in another field can explore direct entry msn online programs. These programs offer an accelerated route into advanced practice nursing and can help you pivot into healthcare without starting from scratch.

For a streamlined path into nursing, some of the adn programs provide accessible entry-level training and can often be completed more quickly than four-year degrees.

Additionally, for those interested in the administrative side of healthcare, certified billing and coding roles are in high demand. Many students ask, can you get financial aid for medical billing and coding? The answer is yes—there are accredited online options with financial support to help you get started.

Best Scientists Citing Stan B. Kaye

Trending Scientists

Recently Published Articles